<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156299</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000540303</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>020201</secondary_id>
    <nct_id>NCT00156299</nct_id>
  </id_info>
  <brief_title>Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate</brief_title>
  <official_title>A Pilot Study of Nuclear Factor-kappa B (NFkB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help&#xD;
      doctors learn more about changes that occur in cancer cells. It may also help doctors&#xD;
      understand how cancer cells respond to treatment with choline magnesium trisalicylate.&#xD;
&#xD;
      PURPOSE: This pilot clinical trial is studying gene expression in cancer cells during&#xD;
      chemotherapy and the safety of choline magnesium trisalicylate in treating patients with&#xD;
      newly diagnosed acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine temporal changes in leukemic cell NF-kB activity when choline magnesium&#xD;
           trisalicylate is administered during induction chemotherapy in patients with newly&#xD;
           diagnosed acute myeloid leukemia.&#xD;
&#xD;
        -  Determine toxicities of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine patterns of leukemic cell gene expression in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine if NF-kB modulation results in enhanced apoptosis in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, pilot study.&#xD;
&#xD;
      Patients receive oral choline magnesium trisalicylate every 8 hours for 48 hours or&#xD;
      dexamethasone every 6 hours for 48 hours plus choline magnesium trisalicylate every 8 hours&#xD;
      for 48 hours during induction chemotherapy as determined by the primary physician.&#xD;
&#xD;
      Blood is collected at baseline, 24 hours, and 48 hours to assess for changes in NF-kB&#xD;
      expression, apoptosis, and gene expression in leukemic cells.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Replaced by another study&#xD;
  </why_stopped>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Temporal changes in leukemic cell NF-kB activity</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of leukemic cell gene expression after administration of choline magnesium trisalicylate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis related to NF-kB modulation</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Dexamethasone plus Choline Magnesium Trisalicylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone plus Choline Magnesium Trisalicylate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Choline Magnesium Trisalicylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Choline Magnesium Trisalicylate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>choline magnesium trisalicylate</intervention_name>
    <description>1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.</description>
    <arm_group_label>Choline Magnesium Trisalicylate</arm_group_label>
    <arm_group_label>Dexamethasone plus Choline Magnesium Trisalicylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.</description>
    <arm_group_label>Dexamethasone plus Choline Magnesium Trisalicylate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed acute myeloid leukemia&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
          -  Presence of cytogenetic abnormalities must be determined by standard cytogenetics with&#xD;
             or without FISH studies&#xD;
&#xD;
          -  Leukemic blast count &gt; 5,000/mmÂ³ of peripheral blood&#xD;
&#xD;
          -  No acute promyelocytic leukemia (M3)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-3&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST &lt; 3.0 times ULN&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled psychiatric illness that, in the opinion of the principal&#xD;
             investigator, would preclude study compliance&#xD;
&#xD;
          -  No other concurrent medical condition that would preclude study compliance&#xD;
&#xD;
          -  No allergies to any investigational drugs and/or chemotherapeutic agents&#xD;
&#xD;
          -  No upper or lower gastrointestinal (GI) related hemorrhage within the past 6 months as&#xD;
             determined by endoscopy&#xD;
&#xD;
               -  No clinical diagnosis of GI bleeding requiring blood transfusions&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior induction therapy&#xD;
&#xD;
          -  No prior chemotherapy for acute leukemia&#xD;
&#xD;
          -  No concurrent medications that would preclude study compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Strair, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Strair RK, Gharibo M, Schaar D, Rubin A, Harrison J, Aisner J, Lin HC, Lin Y, Goodell L, Anand M, Balsara B, Dudek L, Rabson A, Medina DJ. Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia. Clin Cancer Res. 2008 Nov 15;14(22):7564-8. doi: 10.1158/1078-0432.CCR-08-1390.</citation>
    <PMID>19010875</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Choline magnesium trisalicylate</mesh_term>
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

